Moleculin Biotech

Historical price data

Moleculin Biotech is a clinical-stage company focused on developing novel therapeutics for difficult-to-treat cancers and viruses, with a core mission to overcome the limitations of existing anthracyclines. Its key achievement is the advanced development of Annamycin, a next-generation, non-cardiotoxic anthracycline poised to enter a pivotal Phase 3 trial (MIRACLE) for relapsed/refractory AML. The company's strategy leverages a lean operational model and a multi-pronged pipeline to de-risk development and address significant unmet medical needs in oncology and virology.

A portfolio of proprietary small molecule platforms: next-generation anthracyclines designed to avoid cardiotoxicity and multidrug resistance; immune/transcription modulators targeting p-STAT3; and antimetabolite prodrugs targeting cancer and viral metabolism.